首页 > 最新文献

Therapeutic Drug Monitoring最新文献

英文 中文
Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives. 钙调磷酸酶抑制剂在移植中的药动学增强:优点,缺点和观点。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-24 DOI: 10.1097/FTD.0000000000001288
Smita Pattanaik, Caroline Monchaud

Abstract: The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus. The driver for such research was an endeavor to save costs, as both drugs were expensive due to patent protection. Two CYP inhibitors, ketoconazole and diltiazem, have been extensively studied in this context and continue to be prescribed off-label along with the CNI. It has been observed that using ketoconazole reduces the dose requirement of tacrolimus by about 50% and 30% with diltiazem, which is in conformity with their pharmacological actions. Off-label co-prescription of these drugs with CNI is often encountered in low and middle-income countries. The foremost reason cited is economic. This article collates the evidence from the clinical studies that evaluate the PK-boosting effects of CNI and also reviews the gaps in the current evidence base. The current knowledge prevents the transplant community from making meaningful inferences about the risks and benefits of such strategies. Although the PK-boosting strategy can lead to serious adverse events, emerging evidence suggests that it may be advantageous for individuals with high CNI dose requirements. Hence, PK boosting may be an unmet need in the therapeutics of CNI. Nevertheless, there are several unanswered questions surrounding such use, and therefore, this merits testing in well-designed clinical studies. Moreover, drugs with better safer profiles and a history of successful PK boosting may be considered for evaluation with CNI.

摘要:在FDA批准环孢素a后,钙调磷酸酶抑制剂(CNI)的药代动力学(PK)增强的概念出现了。随后进行了几项研究,到20世纪90年代末,概念的证明得到了很好的证实。下一个重磅免疫抑制剂他克莫司也是如此。由于专利保护,这两种药物都很昂贵,因此进行这种研究的动机是为了节省成本。两种CYP抑制剂,酮康唑和地尔硫卓,已经在这方面进行了广泛的研究,并继续与CNI一起在标签外开处方。经观察,使用酮康唑可使他克莫司用量减少约50%,而使用地尔硫卓可使他克莫司用量减少约30%,这与它们的药理作用是一致的。在低收入和中等收入国家经常遇到这些药物与CNI的超说明书联合处方。最主要的原因是经济原因。本文整理了来自临床研究的证据,评估CNI促进pk的作用,并回顾了目前证据基础的差距。目前的知识阻止了移植社区对这种策略的风险和收益做出有意义的推断。虽然pk增强策略可能导致严重的不良事件,但新出现的证据表明,它可能对CNI剂量要求高的个体有利。因此,在CNI的治疗中,PK增强可能是一个未满足的需求。尽管如此,围绕这种使用仍有一些未解决的问题,因此,值得在精心设计的临床研究中进行测试。此外,具有更好的安全性和成功的PK促进历史的药物可以考虑与CNI进行评估。
{"title":"Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives.","authors":"Smita Pattanaik, Caroline Monchaud","doi":"10.1097/FTD.0000000000001288","DOIUrl":"https://doi.org/10.1097/FTD.0000000000001288","url":null,"abstract":"<p><strong>Abstract: </strong>The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus. The driver for such research was an endeavor to save costs, as both drugs were expensive due to patent protection. Two CYP inhibitors, ketoconazole and diltiazem, have been extensively studied in this context and continue to be prescribed off-label along with the CNI. It has been observed that using ketoconazole reduces the dose requirement of tacrolimus by about 50% and 30% with diltiazem, which is in conformity with their pharmacological actions. Off-label co-prescription of these drugs with CNI is often encountered in low and middle-income countries. The foremost reason cited is economic. This article collates the evidence from the clinical studies that evaluate the PK-boosting effects of CNI and also reviews the gaps in the current evidence base. The current knowledge prevents the transplant community from making meaningful inferences about the risks and benefits of such strategies. Although the PK-boosting strategy can lead to serious adverse events, emerging evidence suggests that it may be advantageous for individuals with high CNI dose requirements. Hence, PK boosting may be an unmet need in the therapeutics of CNI. Nevertheless, there are several unanswered questions surrounding such use, and therefore, this merits testing in well-designed clinical studies. Moreover, drugs with better safer profiles and a history of successful PK boosting may be considered for evaluation with CNI.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":"47 1","pages":"118-140"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of Volumetric Finger-Prick Self-Sampling for Therapeutic Drug Monitoring of Immunosuppressants After Kidney Transplantation: Lessons Learned From the Practice. 在肾移植后免疫抑制剂的 TDM 中实施体积计量指抠自采样:从实践中汲取的经验教训。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-19 DOI: 10.1097/FTD.0000000000001281
Nils Tore Vethe, Anders Åsberg, Stein Bergan, Ida Robertsen, Karsten Midtvedt

Background: Home-based hospital services are becoming increasingly popular, and the addition of remote outpatient appointments after kidney transplantation facilitates more practical and closer follow-up. In this context, finger-prick self-sampling is an important aspect of monitoring of immunosuppressants and biomarkers. Nevertheless, several issues must be addressed to ensure the feasibility and quality when implementing microsampling in clinical practice. We summarize our experiences and opinions in this field.

Methods: This article is based on the authors' experience regarding the laboratory and clinical implementation of finger-prick self-sampling in kidney transplant recipients. The referenced literature is related to the authors' knowledge in this field.

Results: We present considerations for the selection of relevant analytes, key characteristics of selected volumetric sampling tools (Mitra and Capitainer), and the associated sampling pitfalls. In addition, we address the requirements for patients performing finger-prick sampling, appropriate design of methods and workflow, critical points for validation, and aspects related to logistics and digital solutions.

Conclusions: Volumetric finger-prick self-sampling is suitable for monitoring immunosuppressants and certain biomarkers that are relevant to outpatient follow-up after kidney transplantation. We believe that a carefully designed system for the entire workflow, including patient training, will be beneficial in enabling a safe experience for transplant recipients, as well as ensuring overall efficiency and adequate quality. In the future, a combination of immunosuppressants with a wide range of biomarkers has significant potential for use in at-home self-sampling after kidney transplantation.

背景:以家庭为基础的医院服务正变得越来越流行,肾移植后增加远程门诊预约有助于进行更实用、更密切的随访。在这种情况下,指检自我采样是监测免疫抑制剂和生物标志物的一个重要方面。然而,在临床实践中实施微量采样时,必须解决几个问题,以确保其可行性和质量。我们总结了我们在这一领域的经验和观点:本文基于作者在实验室和临床上对肾移植受者实施指尖自采样的经验。参考文献与作者在该领域的知识有关:结果:我们介绍了选择相关分析物的注意事项、所选体积采样工具(Mitra 和 Capitainer)的主要特点以及相关的采样误区。此外,我们还讨论了对进行指尖采样的患者的要求、方法和工作流程的适当设计、验证的关键点以及与物流和数字解决方案相关的方面:体积式指尖采样适用于监测免疫抑制剂和与肾移植术后门诊随访相关的某些生物标志物。我们相信,为整个工作流程(包括患者培训)精心设计的系统将有助于为移植受者提供安全的体验,并确保整体效率和适当的质量。未来,免疫抑制剂与多种生物标志物的结合在肾移植后的居家自我采样中具有巨大的应用潜力。
{"title":"Implementation of Volumetric Finger-Prick Self-Sampling for Therapeutic Drug Monitoring of Immunosuppressants After Kidney Transplantation: Lessons Learned From the Practice.","authors":"Nils Tore Vethe, Anders Åsberg, Stein Bergan, Ida Robertsen, Karsten Midtvedt","doi":"10.1097/FTD.0000000000001281","DOIUrl":"10.1097/FTD.0000000000001281","url":null,"abstract":"<p><strong>Background: </strong>Home-based hospital services are becoming increasingly popular, and the addition of remote outpatient appointments after kidney transplantation facilitates more practical and closer follow-up. In this context, finger-prick self-sampling is an important aspect of monitoring of immunosuppressants and biomarkers. Nevertheless, several issues must be addressed to ensure the feasibility and quality when implementing microsampling in clinical practice. We summarize our experiences and opinions in this field.</p><p><strong>Methods: </strong>This article is based on the authors' experience regarding the laboratory and clinical implementation of finger-prick self-sampling in kidney transplant recipients. The referenced literature is related to the authors' knowledge in this field.</p><p><strong>Results: </strong>We present considerations for the selection of relevant analytes, key characteristics of selected volumetric sampling tools (Mitra and Capitainer), and the associated sampling pitfalls. In addition, we address the requirements for patients performing finger-prick sampling, appropriate design of methods and workflow, critical points for validation, and aspects related to logistics and digital solutions.</p><p><strong>Conclusions: </strong>Volumetric finger-prick self-sampling is suitable for monitoring immunosuppressants and certain biomarkers that are relevant to outpatient follow-up after kidney transplantation. We believe that a carefully designed system for the entire workflow, including patient training, will be beneficial in enabling a safe experience for transplant recipients, as well as ensuring overall efficiency and adequate quality. In the future, a combination of immunosuppressants with a wide range of biomarkers has significant potential for use in at-home self-sampling after kidney transplantation.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":"98-104"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. 依维莫司个性化疗法:国际治疗药物监测和临床毒理学协会第二次共识报告》。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-09-25 DOI: 10.1097/FTD.0000000000001250
Satohiro Masuda, Florian Lemaitre, Markus J Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnson-Davis, Pawel K Kunicki, Roland Lawson, Nuria Lloberas, Pierre Marquet, Olga Millan, Tomoyuki Mizuno, Dirk Jan A R Moes, Ofelia Noceti, Michael Oellerich, Smita Pattanaik, Tomasz Pawinski, Christoph Seger, Ron van Schaik, Raman Venkataramanan, Phil Walson, Jean-Baptiste Woillard, Loralie J Langman

Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.

摘要:国际治疗药物监测和临床毒理学协会免疫抑制药物科学委员会在2016年发布第一版报告7年后,制定了第二版共识报告,以指导依维莫司(EVR)的治疗药物监测(TDM)及其在临床实践中的优化使用。这一版本重点介绍了过去 7 年中出现的新进展。关于 EVR 的药理学和 TDM 的一般内容,读者可参考 2016 年的文件。本版纳入了来自文献的新证据,重点关注过去 7 年中更新的主题,包括 EVR 对哺乳动物雷帕霉素靶点复合物 2 的间接药理作用,以及直接抑制哺乳动物雷帕霉素靶点复合物 1 的主要机制。此外,还包括监测 EVR 浓度、改善分析性能和增加免疫化学分析方法可选项的各种概念和技术方案。有关 EVR 的新药物遗传学信息还很有限;不过,已利用生理参数作为协变量(包括药物遗传学信息)构建了药物计量学和模型信息精确给药。在临床环境中,EVR 与降低剂量的钙神经蛋白抑制剂(如他克莫司和环孢素)结合使用,而不是与霉酚酸结合使用。针对特定器官移植(如肾脏、肝脏、心脏和肺)以及肿瘤和儿科的文献和建议也已更新。本版新增了胰腺和胰岛移植的 EVR TDM。器官移植中 EVR 的药效学监测也已更新。这些更新和补充内容以及本共识文件的上一版本将对治疗接受 EVR 患者的临床医生和研究人员有所帮助。
{"title":"Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.","authors":"Satohiro Masuda, Florian Lemaitre, Markus J Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnson-Davis, Pawel K Kunicki, Roland Lawson, Nuria Lloberas, Pierre Marquet, Olga Millan, Tomoyuki Mizuno, Dirk Jan A R Moes, Ofelia Noceti, Michael Oellerich, Smita Pattanaik, Tomasz Pawinski, Christoph Seger, Ron van Schaik, Raman Venkataramanan, Phil Walson, Jean-Baptiste Woillard, Loralie J Langman","doi":"10.1097/FTD.0000000000001250","DOIUrl":"10.1097/FTD.0000000000001250","url":null,"abstract":"<p><strong>Abstract: </strong>The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":"4-31"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Narrative Review of Chromatographic Bioanalytical Methods for Quantifying Everolimus in Therapeutic Drug Monitoring Applications. 用于治疗药物监测应用中依维莫司定量的色谱生物分析方法综述。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-10-24 DOI: 10.1097/FTD.0000000000001273
Julia O Nascimento, Edlaine R Costa, Rita Estrela, Fernanda L Moreira

Background: Methods for measuring drug levels in the body are crucial for improving therapeutic drug monitoring (TDM) and personalized medicine. In solid-organ transplants, TDM is essential for the management of immunosuppressive drugs to avoid toxicity and organ rejection. Everolimus is a commonly used immunosuppressant with a small range of safe doses; therefore, it is important to adjust the dose according to each patient's needs. Therefore, reliable methods are required to accurately measure everolimus levels. This study aims to conduct a comprehensive and updated narrative review of chromatographic bioanalytical methods for everolimus quantification.

Methods: The authors searched for original research articles published between 2013 and 2023 in Scopus and PubMed and found 295 articles after removing duplicates. Based on their titles and summaries, 30 articles were selected for a detailed review and 25 articles were included in the final analysis.

Results: Among the 25 studies, 16 used protein precipitation, mainly with methanol, to prepare the samples, 12 used high-performance liquid chromatography, 11 used ultra-performance liquid chromatography, and 2 used both. Almost all the studies (24 of 25) used tandem mass spectrometry for detection, whereas only 1 used ultraviolet.

Conclusions: This comprehensive review of bioanalytical methods for measuring everolimus using chromatography is a useful resource for researchers developing bioanalytical methods for TDM applications. Future trends in everolimus measurement include achieving lower detection limits, owing to the trend of reducing drug doses in therapy by improving sample extraction techniques and using more sensitive methods.

背景:测量体内药物水平的方法对于改善治疗药物监测(TDM)和个性化医疗至关重要。在实体器官移植中,TDM 对免疫抑制剂的管理至关重要,以避免毒性和器官排斥反应。依维莫司是一种常用的免疫抑制剂,其安全剂量范围较小;因此,根据每位患者的需求调整剂量非常重要。因此,需要可靠的方法来准确测量依维莫司的水平。本研究旨在对依维莫司定量的色谱生物分析方法进行全面、最新的综述:作者在 Scopus 和 PubMed 上搜索了 2013 年至 2023 年间发表的原创研究文章,在删除重复文章后共找到 295 篇文章。根据这些文章的标题和摘要,作者选择了 30 篇文章进行详细审查,并将 25 篇文章纳入最终分析:在这 25 篇研究中,16 篇使用蛋白质沉淀法(主要是甲醇沉淀法)制备样本,12 篇使用高效液相色谱法,11 篇使用超高效液相色谱法,2 篇同时使用这两种方法。几乎所有的研究(25 项中的 24 项)都使用串联质谱进行检测,只有 1 项使用紫外检测:这篇关于使用色谱法测量依维莫司的生物分析方法的综述是研究人员为 TDM 应用开发生物分析方法的有用资源。依维莫司测量的未来趋势包括通过改进样品提取技术和使用更灵敏的方法来降低药物剂量,从而实现更低的检测限。
{"title":"A Narrative Review of Chromatographic Bioanalytical Methods for Quantifying Everolimus in Therapeutic Drug Monitoring Applications.","authors":"Julia O Nascimento, Edlaine R Costa, Rita Estrela, Fernanda L Moreira","doi":"10.1097/FTD.0000000000001273","DOIUrl":"10.1097/FTD.0000000000001273","url":null,"abstract":"<p><strong>Background: </strong>Methods for measuring drug levels in the body are crucial for improving therapeutic drug monitoring (TDM) and personalized medicine. In solid-organ transplants, TDM is essential for the management of immunosuppressive drugs to avoid toxicity and organ rejection. Everolimus is a commonly used immunosuppressant with a small range of safe doses; therefore, it is important to adjust the dose according to each patient's needs. Therefore, reliable methods are required to accurately measure everolimus levels. This study aims to conduct a comprehensive and updated narrative review of chromatographic bioanalytical methods for everolimus quantification.</p><p><strong>Methods: </strong>The authors searched for original research articles published between 2013 and 2023 in Scopus and PubMed and found 295 articles after removing duplicates. Based on their titles and summaries, 30 articles were selected for a detailed review and 25 articles were included in the final analysis.</p><p><strong>Results: </strong>Among the 25 studies, 16 used protein precipitation, mainly with methanol, to prepare the samples, 12 used high-performance liquid chromatography, 11 used ultra-performance liquid chromatography, and 2 used both. Almost all the studies (24 of 25) used tandem mass spectrometry for detection, whereas only 1 used ultraviolet.</p><p><strong>Conclusions: </strong>This comprehensive review of bioanalytical methods for measuring everolimus using chromatography is a useful resource for researchers developing bioanalytical methods for TDM applications. Future trends in everolimus measurement include achieving lower detection limits, owing to the trend of reducing drug doses in therapy by improving sample extraction techniques and using more sensitive methods.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":"49-63"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miRNAs, dd-cf-DNA, and Chemokines as Potential Noninvasive Biomarkers for the Assessment of Clinical Graft Evolution and Personalized Immunosuppression Requirement in Solid Organ Transplantation. miRNA、dd-cf-DNA 和趋化因子是评估实体器官移植中临床移植物演变和个性化免疫抑制需求的潜在非侵入性生物标记物。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-05 DOI: 10.1097/FTD.0000000000001276
Olga Millán, Judit Julian, Mercè Brunet

Abstract: The use of noninvasive biomarkers may reduce the need for biopsy and guide immunosuppression adjustments during transplantation. The scientific community in solid organ transplantation currently considers that chemokines, T- and B-cell immunophenotypes, and gene expression, among other molecular biomarkers, have great potential as diagnostic and predictive biomarkers for graft evolution; however, in clinical practice, few valid early biomarkers have emerged. This review focuses on the most relevant scientific advances in this field in the last 5 years regarding the role of 3 biomarkers: miRNAs, chemokines, and ddcf-DNA, in both adult and pediatric populations. An update was provided on the scores based on the combination of these biomarkers. The most-featured articles were identified through a literature search of the PubMed database. This review provides a comprehensive analysis of the potential clinical applications of these biomarkers in the diagnosis and prediction of graft outcomes and discusses the reasons why none have been implemented in clinical practice to date. Translating these biomarkers into routine clinical practice and combining them with pharmacogenetics and pharmacokinetic monitoring is challenging; however, it is the key to present/future individualized immunosuppressive therapies. It is essential that they be shown to be applicable and robust in real-life patient conditions and properly evaluate their added value when combined with the standard-of-care factor monitoring for graft clinical assessment. Partnership strategies among scientists, academic institutions, consortia, including expert working groups and scientific societies, and pharmaceutical and/or biotechnology companies should promote the development of prospective, randomized, multicenter intervention studies for adequate clinical validation of these biomarkers and their monitoring frequency, and their commercialization to make them available to transplant physicians.

摘要:非侵入性生物标志物的使用可减少活组织检查的需要,并指导移植过程中免疫抑制的调整。目前,实体器官移植领域的科学界认为,趋化因子、T 细胞和 B 细胞免疫表型以及基因表达等分子生物标志物作为诊断和预测移植物演变的生物标志物具有巨大的潜力;然而,在临床实践中,有效的早期生物标志物却寥寥无几。本综述重点介绍了过去五年中该领域最相关的科学进展,涉及 miRNA、趋化因子和 ddcf-DNA 这三种生物标志物在成人和儿童人群中的作用。根据这些生物标志物的组合对评分进行了更新。通过对 PubMed 数据库进行文献检索,确定了最具特色的文章。本综述全面分析了这些生物标志物在诊断和预测移植物预后方面的潜在临床应用,并讨论了迄今为止尚未在临床实践中应用的原因。将这些生物标志物转化为常规临床实践并与药物遗传学和药代动力学监测相结合具有挑战性;然而,这是目前/未来个体化免疫抑制疗法的关键。至关重要的是,必须证明它们在实际患者病情中的适用性和稳健性,并适当评估它们与移植物临床评估的标准护理因子监测相结合后的附加值。科学家、学术机构、联合体(包括专家工作组和科学协会)以及制药和/或生物技术公司之间的合作战略应促进前瞻性、随机、多中心干预研究的发展,以便对这些生物标志物及其监测频率进行充分的临床验证,并促进其商业化,使移植医生能够获得这些生物标志物。
{"title":"miRNAs, dd-cf-DNA, and Chemokines as Potential Noninvasive Biomarkers for the Assessment of Clinical Graft Evolution and Personalized Immunosuppression Requirement in Solid Organ Transplantation.","authors":"Olga Millán, Judit Julian, Mercè Brunet","doi":"10.1097/FTD.0000000000001276","DOIUrl":"10.1097/FTD.0000000000001276","url":null,"abstract":"<p><strong>Abstract: </strong>The use of noninvasive biomarkers may reduce the need for biopsy and guide immunosuppression adjustments during transplantation. The scientific community in solid organ transplantation currently considers that chemokines, T- and B-cell immunophenotypes, and gene expression, among other molecular biomarkers, have great potential as diagnostic and predictive biomarkers for graft evolution; however, in clinical practice, few valid early biomarkers have emerged. This review focuses on the most relevant scientific advances in this field in the last 5 years regarding the role of 3 biomarkers: miRNAs, chemokines, and ddcf-DNA, in both adult and pediatric populations. An update was provided on the scores based on the combination of these biomarkers. The most-featured articles were identified through a literature search of the PubMed database. This review provides a comprehensive analysis of the potential clinical applications of these biomarkers in the diagnosis and prediction of graft outcomes and discusses the reasons why none have been implemented in clinical practice to date. Translating these biomarkers into routine clinical practice and combining them with pharmacogenetics and pharmacokinetic monitoring is challenging; however, it is the key to present/future individualized immunosuppressive therapies. It is essential that they be shown to be applicable and robust in real-life patient conditions and properly evaluate their added value when combined with the standard-of-care factor monitoring for graft clinical assessment. Partnership strategies among scientists, academic institutions, consortia, including expert working groups and scientific societies, and pharmaceutical and/or biotechnology companies should promote the development of prospective, randomized, multicenter intervention studies for adequate clinical validation of these biomarkers and their monitoring frequency, and their commercialization to make them available to transplant physicians.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":"77-97"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships Between Tacrolimus Exposure and Adverse Events in Renal Transplant Patients: The ExpoTac Study. 他克莫司暴露与肾移植患者不良事件的关系:ExpoTac研究
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-03 DOI: 10.1097/FTD.0000000000001287
Caroline Monchaud, Antoine Humeau, Sabrina Crépin, Lama Kawsarani, Claire Villeneuve, Isabelle Etienne, Jean-Philippe Rerolle, Pierre Marquet

Abstract: In transplantation, the association of tacrolimus exposure with efficacy is better known than with adverse effects. The ExpoTac study explored the relationships between tacrolimus exposure and adverse events (AEs) in kidney transplant patients who benefited from at least 3 measurements of tacrolimus area under the curve (AUC) within 2 years of transplantation. The relationships between tacrolimus AUC, trough concentration C 0 , peak concentration C max , and AEs were explored using univariate analysis and Cox models in 386 patients (1281 sets of exposure biomarkers). Headaches and renal impairment potentially induced by tacrolimus were associated with significantly lower mean dose-standardized exposure biomarkers and a higher proportion of C max values above the median. Patients with tremor displayed significantly higher mean AUC 0-24 (343 ± 79 versus 308 ± 63 hours·mcg/L, P = 0.041). Cox analysis revealed a significant association between (1) the time to the first headache report and mean C max , mean AUC 0-24 , and the proportion of C max values above the median (hazard ratios [95% confidence interval] = 0.237 [0.007-0.538]; 7.499 [1.508-29.713]; 5.055 [1.577-17.137]) and (2) the time to first renal impairment report and the proportion of C 0 values above the median (0.401 [0.098-0.681]). Refining AUC, C max , and C 0 upper limits would help to refine tacrolimus therapeutic ranges and limit the risks of AEs after kidney transplantation.

摘要:在移植中,他克莫司暴露与疗效的关系比与不良反应的关系更广为人知。ExpoTac研究探讨了他克莫司暴露与肾移植患者不良事件(ae)之间的关系,这些患者在移植后2年内至少接受了3次他克莫司曲线下面积(AUC)测量。采用单因素分析和Cox模型对386例患者(1281组暴露生物标志物)他克莫司AUC、谷浓度C0、峰浓度Cmax与ae之间的关系进行了探讨。他克莫司可能引起的头痛和肾脏损害与平均剂量标准化暴露生物标志物显著降低和Cmax值高于中位数的比例较高相关。震颤患者的平均AUC0-24(343±79比308±63小时·mcg/L, P = 0.041)明显高于震颤患者。Cox分析显示:(1)首次头痛报告的时间与平均Cmax、平均AUC0-24和Cmax值高于中位数的比例存在显著相关(风险比[95%置信区间]= 0.237 [0.007-0.538];7.499 (1.508 - -29.713);5.055[1.577-17.137])和(2)首次报告肾功能损害的时间和C0值高于中位数的比例(0.401[0.098-0.681])。细化AUC、Cmax和C0上限将有助于细化他克莫司的治疗范围,限制肾移植后不良反应的风险。
{"title":"Relationships Between Tacrolimus Exposure and Adverse Events in Renal Transplant Patients: The ExpoTac Study.","authors":"Caroline Monchaud, Antoine Humeau, Sabrina Crépin, Lama Kawsarani, Claire Villeneuve, Isabelle Etienne, Jean-Philippe Rerolle, Pierre Marquet","doi":"10.1097/FTD.0000000000001287","DOIUrl":"10.1097/FTD.0000000000001287","url":null,"abstract":"<p><strong>Abstract: </strong>In transplantation, the association of tacrolimus exposure with efficacy is better known than with adverse effects. The ExpoTac study explored the relationships between tacrolimus exposure and adverse events (AEs) in kidney transplant patients who benefited from at least 3 measurements of tacrolimus area under the curve (AUC) within 2 years of transplantation. The relationships between tacrolimus AUC, trough concentration C 0 , peak concentration C max , and AEs were explored using univariate analysis and Cox models in 386 patients (1281 sets of exposure biomarkers). Headaches and renal impairment potentially induced by tacrolimus were associated with significantly lower mean dose-standardized exposure biomarkers and a higher proportion of C max values above the median. Patients with tremor displayed significantly higher mean AUC 0-24 (343 ± 79 versus 308 ± 63 hours·mcg/L, P = 0.041). Cox analysis revealed a significant association between (1) the time to the first headache report and mean C max , mean AUC 0-24 , and the proportion of C max values above the median (hazard ratios [95% confidence interval] = 0.237 [0.007-0.538]; 7.499 [1.508-29.713]; 5.055 [1.577-17.137]) and (2) the time to first renal impairment report and the proportion of C 0 values above the median (0.401 [0.098-0.681]). Refining AUC, C max , and C 0 upper limits would help to refine tacrolimus therapeutic ranges and limit the risks of AEs after kidney transplantation.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":"152-160"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Drug Monitoring of Immunosuppressive Drugs: A Field Constantly in Motion. 免疫抑制药物的治疗药物监测:一个不断运动的领域。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-20 DOI: 10.1097/FTD.0000000000001286
Maria Shipkova, Florian Lemaitre
{"title":"Therapeutic Drug Monitoring of Immunosuppressive Drugs: A Field Constantly in Motion.","authors":"Maria Shipkova, Florian Lemaitre","doi":"10.1097/FTD.0000000000001286","DOIUrl":"https://doi.org/10.1097/FTD.0000000000001286","url":null,"abstract":"","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":"47 1","pages":"1-3"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Customizing Tacrolimus Dosing in Kidney Transplantation: Focus on Pharmacogenetics. 定制他克莫司在肾移植中的剂量:关注药物遗传学。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-10 DOI: 10.1097/FTD.0000000000001289
Nuria Lloberas, Anna Vidal-Alabró, Helena Colom

Abstract: Different polymorphisms in genes encoding metabolizing enzymes and drug transporters have been associated with tacrolimus pharmacokinetics. In particular, studies on CYP3A4 and CYP3A5, and their combined cluster have demonstrated their significance in adjusting tacrolimus dosing to minimize under- and overexposure thereby increasing the proportion of patients who achieve tacrolimus therapeutic target. Many factors influence the pharmacokinetics of tacrolimus, contributing to inter-patient variability affecting individual dosing requirements. On the other hand, the growing use of population pharmacokinetic models in solid organ transplantation, including different tacrolimus formulations, has facilitated the integration of pharmacogenetic data and other variables into algorithms to easier implement the personalized dose adjustment in transplant centers. The future of personalized medicine in transplantation lies in implementing these models in clinical practice, with pharmacogenetics as a key factor to account for the high inter-patient variability in tacrolimus exposure. To date, three clinical trials have validated the clinical application of these approaches. The aim of this review is to provide an overview of the current studies regarding the different population pharmacokinetic including pharmacogenetics and those translated to the clinical practice for individualizing tacrolimus dose adjustment in kidney transplantation.

摘要:代谢酶和药物转运蛋白编码基因的不同多态性与他克莫司的药代动力学有关。特别是CYP3A4和CYP3A5及其联合簇的研究已经证明了它们在调整他克莫司剂量以减少不足和过度暴露从而增加达到他克莫司治疗目标的患者比例方面的重要意义。许多因素影响他克莫司的药代动力学,导致患者之间的差异影响个体剂量需求。另一方面,群体药代动力学模型在实体器官移植(包括不同的他克莫司制剂)中的应用越来越多,这有助于将药理学数据和其他变量整合到算法中,从而更容易在移植中心实现个性化剂量调整。移植个体化医疗的未来在于在临床实践中实施这些模型,药物遗传学是解释他克莫司暴露的高患者间变异性的关键因素。迄今为止,已有三个临床试验验证了这些方法的临床应用。这篇综述的目的是提供关于不同人群药代动力学的研究综述,包括药物遗传学和那些转化为临床实践的肾移植个体化他克莫司剂量调整。
{"title":"Customizing Tacrolimus Dosing in Kidney Transplantation: Focus on Pharmacogenetics.","authors":"Nuria Lloberas, Anna Vidal-Alabró, Helena Colom","doi":"10.1097/FTD.0000000000001289","DOIUrl":"https://doi.org/10.1097/FTD.0000000000001289","url":null,"abstract":"<p><strong>Abstract: </strong>Different polymorphisms in genes encoding metabolizing enzymes and drug transporters have been associated with tacrolimus pharmacokinetics. In particular, studies on CYP3A4 and CYP3A5, and their combined cluster have demonstrated their significance in adjusting tacrolimus dosing to minimize under- and overexposure thereby increasing the proportion of patients who achieve tacrolimus therapeutic target. Many factors influence the pharmacokinetics of tacrolimus, contributing to inter-patient variability affecting individual dosing requirements. On the other hand, the growing use of population pharmacokinetic models in solid organ transplantation, including different tacrolimus formulations, has facilitated the integration of pharmacogenetic data and other variables into algorithms to easier implement the personalized dose adjustment in transplant centers. The future of personalized medicine in transplantation lies in implementing these models in clinical practice, with pharmacogenetics as a key factor to account for the high inter-patient variability in tacrolimus exposure. To date, three clinical trials have validated the clinical application of these approaches. The aim of this review is to provide an overview of the current studies regarding the different population pharmacokinetic including pharmacogenetics and those translated to the clinical practice for individualizing tacrolimus dose adjustment in kidney transplantation.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":"47 1","pages":"141-151"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Developments and Therapeutic Drug Monitoring Options in Costimulatory Blockade in Solid Organ Transplantation: A Systematic Critical Review. 实体器官移植中 Costimulatory Blockade 的新进展和治疗药物监测选择:系统性评论。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-20 DOI: 10.1097/FTD.0000000000001275
Gretchen N de Graav, Suwasin Udomkarnjananun, Carla C Baan, Marlies E J Reinders, Joke I Roodnat, Brenda C M de Winter, Dennis A Hesselink

Purpose: In this review, the authors summarized the latest developments in costimulatory blockade to prevent rejection after solid organ transplantation (SOT) and discussed possibilities for future research and the need for therapeutic drug monitoring (TDM) of these agents.

Methods: Studies about costimulatory blockers in SOT in humans or animal transplant models in the past decade (2014-2024) were systematically reviewed in PubMed, European Union clinical trials (EudraCT), and ClinicalTrials.gov .

Results: Seventy-five registered clinical trials and 58 published articles were found on costimulation blockade of the CD28-CD80/86, CD40-CD40L, and OX40-OX40L pathways. Belatacept, an antagonist of the CD28-CD80/86 pathway, is the only approved costimulatory agent in SOT, hence accounting for most of the research. Other identified costimulatory blocking agents included abatacept and CD28 antagonists tegoprubart, dazodalibep, and TNX-1500. Although tegoprubart was unsuccessful in pancreas transplantation in nonhuman primates, trials in human kidney transplantation are underway. Dazodalibep trials faced recruitment challenges. TNX-1500 was unsuccessful in animal studies and is currently not pursued in humans. After discontinuation of iscalimab (CD40-CD154 pathway antagonist) in SOT, the alternatives, bleselumab and KPL404, showed promising results in kidney transplantation and cardiac xenotransplantation. Studies on secondary costimulatory pathway antagonists, such as OX40-OX40L, have only used animal models. Despite the low interindividual variability in pharmacokinetics (PK) in all studied agents, TDM could be useful for optimizing dosing in PK/pharmacodynamic (PD) studies.

Conclusions: The routine use of costimulation blockade in SOT is hindered by problems in efficacy compared with the standard of care. Costimulatory inhibitors could be combined in a calcineurin inhibitor-free regimen. Future PK/pharmacodynamic studies in costimulatory agents and personalized medicine could warrant TDM of these agents.

目的:在这篇综述中,作者总结了成本刺激阻断剂在预防实体器官移植(SOT)后排斥反应方面的最新进展,并讨论了未来研究的可能性以及对这些药物进行治疗药物监测(TDM)的必要性:方法:在PubMed、欧盟临床试验(EudraCT)和ClinicalTrials.gov.Results.中系统回顾了过去十年(2014-2024年)在人体或动物移植模型中使用成本刺激阻断剂治疗SOT的研究:结果:共发现75项注册临床试验和58篇已发表文章,内容涉及CD28-CD80/86、CD40-CD40L和OX40-OX40L途径的成本刺激阻断。贝拉替塞(Belatacept)是 CD28-CD80/86 通路的拮抗剂,也是唯一获准用于 SOT 的成本刺激药物,因此占据了大部分研究内容。其他已确定的成本刺激阻断剂包括阿巴他赛普特和 CD28 拮抗剂 tegoprubart、dazodalibep 和 TNX-1500。虽然 Tegoprubart 在非人灵长类的胰腺移植中没有取得成功,但在人类肾脏移植中的试验正在进行中。Dazodalibep试验面临招募困难。TNX-1500 在动物实验中未取得成功,目前也未用于人体。在 SOT 中停止使用异卡利单抗(CD40-CD154 通路拮抗剂)后,替代药物 bleselumab 和 KPL404 在肾移植和心脏异种移植中显示出良好的效果。关于次级激动通路拮抗剂(如 OX40-OX40L)的研究仅使用了动物模型。尽管所有研究药物的药代动力学(PK)个体间变异性较低,但TDM可用于优化PK/药效学(PD)研究中的剂量:结论:与标准治疗相比,成本刺激阻滞剂在 SOT 中的常规使用因疗效问题而受到阻碍。成本刺激抑制剂可与不含降钙素酶抑制剂的治疗方案相结合。未来对成本刺激剂和个性化药物的 PK/药效学研究可能会为这些药物的 TDM 提供依据。
{"title":"New Developments and Therapeutic Drug Monitoring Options in Costimulatory Blockade in Solid Organ Transplantation: A Systematic Critical Review.","authors":"Gretchen N de Graav, Suwasin Udomkarnjananun, Carla C Baan, Marlies E J Reinders, Joke I Roodnat, Brenda C M de Winter, Dennis A Hesselink","doi":"10.1097/FTD.0000000000001275","DOIUrl":"10.1097/FTD.0000000000001275","url":null,"abstract":"<p><strong>Purpose: </strong>In this review, the authors summarized the latest developments in costimulatory blockade to prevent rejection after solid organ transplantation (SOT) and discussed possibilities for future research and the need for therapeutic drug monitoring (TDM) of these agents.</p><p><strong>Methods: </strong>Studies about costimulatory blockers in SOT in humans or animal transplant models in the past decade (2014-2024) were systematically reviewed in PubMed, European Union clinical trials (EudraCT), and ClinicalTrials.gov .</p><p><strong>Results: </strong>Seventy-five registered clinical trials and 58 published articles were found on costimulation blockade of the CD28-CD80/86, CD40-CD40L, and OX40-OX40L pathways. Belatacept, an antagonist of the CD28-CD80/86 pathway, is the only approved costimulatory agent in SOT, hence accounting for most of the research. Other identified costimulatory blocking agents included abatacept and CD28 antagonists tegoprubart, dazodalibep, and TNX-1500. Although tegoprubart was unsuccessful in pancreas transplantation in nonhuman primates, trials in human kidney transplantation are underway. Dazodalibep trials faced recruitment challenges. TNX-1500 was unsuccessful in animal studies and is currently not pursued in humans. After discontinuation of iscalimab (CD40-CD154 pathway antagonist) in SOT, the alternatives, bleselumab and KPL404, showed promising results in kidney transplantation and cardiac xenotransplantation. Studies on secondary costimulatory pathway antagonists, such as OX40-OX40L, have only used animal models. Despite the low interindividual variability in pharmacokinetics (PK) in all studied agents, TDM could be useful for optimizing dosing in PK/pharmacodynamic (PD) studies.</p><p><strong>Conclusions: </strong>The routine use of costimulation blockade in SOT is hindered by problems in efficacy compared with the standard of care. Costimulatory inhibitors could be combined in a calcineurin inhibitor-free regimen. Future PK/pharmacodynamic studies in costimulatory agents and personalized medicine could warrant TDM of these agents.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":"64-76"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining Whole Blood, Total and Free Plasma Tacrolimus in Elderly Kidney Transplant Recipients. 老年肾移植受者全血、总血浆和游离血浆他克莫司的检测。
IF 2.8 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-01 Epub Date: 2024-11-07 DOI: 10.1097/FTD.0000000000001274
Amelia R Cossart, Nicole M Isbel, Scott B Campbell, Brett McWhinney, Christine E Staatz

Background: Therapeutic monitoring is routinely performed to ensure tacrolimus whole-blood concentrations fall within a predefined target. Despite this, patients still experience inefficacy and toxicity that could be related to variability in free (unbound) tacrolimus exposure. Therefore, the aim of this study was to compare tacrolimus-free plasma (C u ), total plasma (C p ), and whole-blood (C wb ) concentrations in adult kidney transplant recipients and to characterize tacrolimus disposition across different matrices.

Methods: Twelve-hour concentration-time profiling was performed in 15 recipients, allowing simultaneous measurement of C u , C p , and C wb . Pharmacokinetic parameters were estimated using noncompartmental analysis. The relationship between C wb and C p were examined using a capacity-limited binding model, incorporating the hematocrit fraction ( fHCT ) to estimate maximum binding concentration ( Bmax ) and dissociation constant ( Kd ). The relationship between C p and C u was evaluated using a linear binding model to estimate the nonspecific binding parameter ( Nplasma ). Nonlinear regression analysis was used to obtain estimates of Bmax , Kd , and Nplasma .

Results: A total of 195 paired C wb , C p , and C u values were collected. The median ratios of C wb :C p , C p :C u , and C wb :C u were 9:1, 20:1, and 138:1, respectively. Variability in free plasma exposure was large; free trough values ranged from 8 to 51 ng/L and free area-under-the-concentration-time-curve values ranged from 424 to 7160 ng·h/L. Median (range) estimates of Bmax , Kd , and Nplasma were 90.4 µg/L (22.4-752.5 µg/L), 2.36 µg/L (0-69.2 µg/L), and 0.05 (0.035-0.085), respectively. The interindividual variability (CV%) in binding parameters was considerable ( Bmax 117.2%; Nplasma 32.5%).

Conclusions: Large variability was observed in tacrolimus-free plasma exposure and binding parameters. Future research to characterize the relationship between tacrolimus C u and patient outcomes may be of benefit.

背景:常规进行治疗监测以确保他克莫司全血浓度落在预定目标范围内。尽管如此,患者仍然会经历无效和毒性,这可能与游离(未结合)他克莫司暴露的可变性有关。因此,本研究的目的是比较成人肾移植受者无他克莫司血浆(cu)、总血浆(cp)和全血(cwb)浓度,并表征他克莫司在不同基质中的配置。方法:对15名受者进行12小时浓度-时间分析,允许同时测量cu, cp和cwb。采用非区室分析估计药代动力学参数。使用容量限制结合模型,结合红细胞压积分数(fHCT)来估计最大结合浓度(Bmax)和解离常数(Kd)来检验cwb和cp之间的关系。利用线性结合模型估计非特异性结合参数(Nplasma)来评估cp和cu之间的关系。结果:共收集到195个配对的cwb、cp和cu值。cwb: cp、cp: cu和cwb: cu的中位数比值分别为9:1、20:1和138:1。游离血浆暴露的可变性很大;自由谷值为8 ~ 51 ng/L,浓度-时间曲线下自由面积为424 ~ 7160 ng·h/L。Bmax、Kd和Nplasma的中位值(范围)分别为90.4µg/L(22.4-752.5µg/L)、2.36µg/L(0-69.2µg/L)和0.05(0.035-0.085)。结合参数的个体间变异(CV%)相当大(Bmax 117.2%;Nplasma 32.5%)。结论:在无他克莫司的血浆暴露和结合参数中观察到很大的变异性。未来研究他克莫司C u与患者预后之间的关系可能是有益的。
{"title":"Examining Whole Blood, Total and Free Plasma Tacrolimus in Elderly Kidney Transplant Recipients.","authors":"Amelia R Cossart, Nicole M Isbel, Scott B Campbell, Brett McWhinney, Christine E Staatz","doi":"10.1097/FTD.0000000000001274","DOIUrl":"10.1097/FTD.0000000000001274","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic monitoring is routinely performed to ensure tacrolimus whole-blood concentrations fall within a predefined target. Despite this, patients still experience inefficacy and toxicity that could be related to variability in free (unbound) tacrolimus exposure. Therefore, the aim of this study was to compare tacrolimus-free plasma (C u ), total plasma (C p ), and whole-blood (C wb ) concentrations in adult kidney transplant recipients and to characterize tacrolimus disposition across different matrices.</p><p><strong>Methods: </strong>Twelve-hour concentration-time profiling was performed in 15 recipients, allowing simultaneous measurement of C u , C p , and C wb . Pharmacokinetic parameters were estimated using noncompartmental analysis. The relationship between C wb and C p were examined using a capacity-limited binding model, incorporating the hematocrit fraction ( fHCT ) to estimate maximum binding concentration ( Bmax ) and dissociation constant ( Kd ). The relationship between C p and C u was evaluated using a linear binding model to estimate the nonspecific binding parameter ( Nplasma ). Nonlinear regression analysis was used to obtain estimates of Bmax , Kd , and Nplasma .</p><p><strong>Results: </strong>A total of 195 paired C wb , C p , and C u values were collected. The median ratios of C wb :C p , C p :C u , and C wb :C u were 9:1, 20:1, and 138:1, respectively. Variability in free plasma exposure was large; free trough values ranged from 8 to 51 ng/L and free area-under-the-concentration-time-curve values ranged from 424 to 7160 ng·h/L. Median (range) estimates of Bmax , Kd , and Nplasma were 90.4 µg/L (22.4-752.5 µg/L), 2.36 µg/L (0-69.2 µg/L), and 0.05 (0.035-0.085), respectively. The interindividual variability (CV%) in binding parameters was considerable ( Bmax 117.2%; Nplasma 32.5%).</p><p><strong>Conclusions: </strong>Large variability was observed in tacrolimus-free plasma exposure and binding parameters. Future research to characterize the relationship between tacrolimus C u and patient outcomes may be of benefit.</p>","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":"47 1","pages":"161-168"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142962435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Drug Monitoring
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1